SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 12.8% Stake in Day One Biopharmaceuticals

FMR LLC and its Chief Executive Officer, Abigail P. Johnson, have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 12.8% of Day One Biopharmaceuticals Inc.'s common stock as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson, its CEO, jointly reported beneficial ownership of 12,887,467.14 shares of common stock in DAY ONE BIOPHARMACEUTICALS INC.
• This aggregate amount represents 12.8% of the total outstanding common stock of DAY ONE BIOPHARMACEUTICALS INC.
• FMR LLC holds sole voting power over 12,866,297.00 shares and sole dispositive power over 12,887,467.14 shares.
• Abigail P. Johnson's beneficial ownership is attributed through her role and family's control of FMR LLC, with sole dispositive power over 12,887,467.14 shares and no sole or shared voting power directly.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change in previously reported ownership or status.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a factual ownership disclosure and does not contain performance-related sentiment. However, a significant stake by a major investment firm like FMR LLC can be viewed as a positive signal of confidence in the issuer, hence a slightly positive score.

Positives

• The disclosure of a significant 12.8% stake by a major institutional investor like FMR LLC, a prominent asset management firm, can be interpreted as a positive signal of confidence in Day One Biopharmaceuticals Inc.'s long-term prospects.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, suggesting a passive investment intent.

Negatives

• This document is a routine ownership disclosure and does not contain information typically categorized as 'negatives' regarding the issuer's performance or outlook.

Risks

• This document is a routine ownership disclosure and does not detail company-specific risks for Day One Biopharmaceuticals Inc.

Future Outlook

NA

Management Comments

• The document includes certifications from FMR LLC and Abigail P. Johnson stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like FMR LLC can influence investor perception and potentially the stock's trading activity, signaling institutional confidence in the company.

Key Dates

Keywords

Day One Biopharmaceuticals Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Ownership Disclosure, Common Stock, Institutional Investor, Biopharmaceuticals, SEC Filing, Investment Management